{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:09:05Z","timestamp":1787792945616,"version":"build-2784847793"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Utilization of Hepatitis B virus (HBV)\u2010infected kidney allografts represents an opportunity to bridge the gap between organ supply and demand. Highly efficacious vaccines and antiviral therapies allow these allografts to be transplanted with negligible risk to the recipient. The purpose of this study was to describe the prophylactic strategies and related clinical outcomes of kidney transplant recipients who received a kidney from an HBV viremic donor. Eight patients received an allograft from an HBV viremic deceased kidney donor between January 1, 2017 and December 4, 2020. All recipients were immune to hepatitis B with a surface antibody titer greater than or equal to 10\u00a0mIU\/ml (range: 12\u00a0\u2010\u00a0&gt;\u00a01000 mIU\/ml). After transplant, 62.5% demonstrated HBV core antibody seroconversion at an average of 47.4 \u00b1 28.5 days post\u2010transplant. Anti\u2010viral prophylaxis was initiated in 87.5% of patients; 62.5% preemptively during the transplant admission (range 1\u20133 days post\u2010transplant) and 25% following HBcAb seroconversion (range 45\u2013304 days post\u2010transplant). Of the four patients who were started on entecavir preemptively, two subsequently core converted. These two patients had an HBV surface antibody less than 100 mIU\/ml at the time of transplant. None of the recipients converted to HBV surface antigen positivity. The average estimated glomerular filtration rate was 41 \u00b1 19\u00a0ml\/min\/1.73m<jats:sup>2<\/jats:sup>, and there were no significant elevations in liver enzymes through one year post\u2010transplant. The use of HBV viremic kidney allografts may represent an additional source of transplant organs; however, more studies are needed to better elucidate the optimal protective strategies for these recipients.<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/tid13872-gra-0001-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text><\/jats:p>","DOI":"10.1111\/tid.13872","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T08:10:37Z","timestamp":1654071037000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of hepatitis B viremic donors in kidney transplant recipients: A single center experience"],"prefix":"10.1111","volume":"24","author":[{"given":"Brooke T.","family":"Carnemolla","sequence":"first","affiliation":[{"name":"Department of Pharmacy Hartford Hospital  Hartford Connecticut USA"},{"name":"Albany College of Pharmacy and Health Sciences  Albany New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0106-9822","authenticated-orcid":false,"given":"Heather L.","family":"Kutzler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hartford Hospital  Hartford Connecticut USA"},{"name":"Transplant and Comprehensive Liver Center Hartford Hospital  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-2075","authenticated-orcid":false,"given":"Hillary A.","family":"Kuzaro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hartford Hospital  Hartford Connecticut USA"},{"name":"Transplant and Comprehensive Liver Center Hartford Hospital  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glyn","family":"Morgan","sequence":"additional","affiliation":[{"name":"Transplant and Comprehensive Liver Center Hartford Hospital  Hartford Connecticut USA"},{"name":"Department of Surgery University of Connecticut School of Medicine  Farmington Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-0938","authenticated-orcid":false,"given":"Oscar K.","family":"Serrano","sequence":"additional","affiliation":[{"name":"Transplant and Comprehensive Liver Center Hartford Hospital  Hartford Connecticut USA"},{"name":"Department of Surgery University of Connecticut School of Medicine  Farmington Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Ye","sequence":"additional","affiliation":[{"name":"Transplant and Comprehensive Liver Center Hartford Hospital  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiqa","family":"Cheema","sequence":"additional","affiliation":[{"name":"Transplant and Comprehensive Liver Center Hartford Hospital  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,9]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"National Kidney Foundation. Organ donation and transplantation statistics. Accessed June 21 2021.https:\/\/www.kidney.org\/news\/newsroom\/factsheets\/Organ\u2010Donation\u2010and\u2010Transplantation\u2010Stats"},{"key":"e_1_2_7_3_1","unstructured":"UCLA Health. Adult kidney transplant. Accessed June 21 2021.https:\/\/www.uclahealth.org\/transplants\/kidney\/adult\u2010transplant"},{"key":"e_1_2_7_4_1","unstructured":"CDC. Hepatitis B question & answers for health care professionals. Accessed June 21 2021.https:\/\/www.cdc.gov\/hepatitis\/hbv\/hbvfaq.htm#overview"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/SLA.0000000000005071","article-title":"Expanding the donor pool: first use of hepatitis B virus nat positive solid organ allografts into seronegative recipients","volume":"274","author":"Delman AM","year":"2021","journal-title":"Ann Surg"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02707.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12921"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy342"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13187"},{"issue":"4","key":"e_1_2_7_10_1","first-page":"501","article-title":"Meta\u2010analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation","volume":"15","author":"Yang C","year":"2016","journal-title":"Ann Hepatol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13036"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.04.011"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa178"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13872","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.13872","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:02:34Z","timestamp":1755514954000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.13872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,9]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/tid.13872"],"URL":"https:\/\/doi.org\/10.1111\/tid.13872","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,9]]},"assertion":[{"value":"2022-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13872"}}